Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110355 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
A Phase 1 study, sponsored by Kartos Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02110355: Completed Phase 1 study, sponsored by Kartos Therapeutics.
NCT02110355 is a Phase 1 study that has completed, run by Kartos Therapeutics. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02110355, a Phase 1 study, has completed, sponsored by Kartos Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
Primary Outcome
Incidence and grade of treatment-emergent adverse events, including dose-limiting toxicities; AMG 232, trametinib, dabrafenib, and metabolite PK parameters; progression-free Survival
Interventions
- DRUG Trametinib
- DRUG Dabrafenib
- DRUG AMG 232
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2014-12-19 |
| Est. Completion | 2018-12-27 |
| Phase | Phase 1 |
What the finished NCT02110355 record still lists
NCT02110355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 3 interventions - of which Trametinib is the first listed.
NCT02110355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02110355 about?
NCT02110355 is a clinical study titled "A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma". Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.
What is the current status of trial NCT02110355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2014-12-19. Estimated completion is 2018-12-27.
What interventions are being tested in trial NCT02110355?
The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), AMG 232 (DRUG).
Who is sponsoring clinical trial NCT02110355?
This trial is sponsored by Kartos Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02110355's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI